In last trading session, Seres Therapeutics Inc (NASDAQ:MCRB) saw 6.81 million shares changing hands with its beta currently measuring 2.14. Company’s recent per share price level of $1.08 trading at $0.09 or 9.02% at ring of the bell on the day assigns it a market valuation of $163.09M. That closing price of MCRB’s stock is at a discount of -479.63% from its 52-week high price of $6.26 and is indicating a premium of 50.0% from its 52-week low price of $0.54. Taking a look at company’s average trading volume volume of 4.28 million if we extend that period to 3-months.
Seres Therapeutics Inc (NASDAQ:MCRB) trade information
Upright in the green during last session for gaining 9.02%, in the last five days MCRB remained trading in the green while hitting it’s week-highest on Wednesday, 05/01/24 when the stock touched $1.08 price level, adding 6.09% to its value on the day. Seres Therapeutics Inc’s shares saw a change of -22.86% in year-to-date performance and have moved 48.05% in past 5-day. Seres Therapeutics Inc (NASDAQ:MCRB) showed a performance of 41.58% in past 30-days.
Seres Therapeutics Inc (MCRB) estimates and forecasts
Statistics highlight that Seres Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -25.52% of value to its shares in past 6 months, showing an annual growth rate of -29.21% while that of industry is 12.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 40.40% in the current quarter and calculating -186.10% decrease in the next quarter. This year revenue growth is estimated to fall -98.90% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $250k for the same. And 6 analysts are in estimates of company making revenue of $250k in the next quarter that will end on Jun 2024. Company posted $1.38 million and $126.47 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -81.90% while estimating it to be -99.80% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 18.22% during past 5 years.
MCRB Dividends
Seres Therapeutics Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
